ARO-DIMER-PA

RNA / oligonucleotide

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Mixed Hyperlipidemia

Competitive landscape

This drug's own stage for Mixed Hyperlipidemia: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
ARO-DIMER-PA: this drugPhase 1/2RNA / oligonucleotidePCSK9/APOC3not yet gradedNo reviewed efficacy summary in this indication
Ezetimibe (Zetia)ApprovedSmall moleculeDietary Cholesterol Absorption Inhibitor, NPC1L1not yet gradedNo reviewed efficacy summary in this indication
Ebronucimab
Phase 3(overall)
Monoclonal antibodyPCSK9not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow ARO-DIMER-PA to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
Phase 1/2Mixed HyperlipidemiaRecruiting
Est. primary completion 2027-07 · NCT07223658 · CT.gov ↗
What to watch

See the full readout calendar ↗